Navigation Links
Cardiac Science Reports Record Fourth Quarter and Full Year 2007 Results
Date:2/28/2008

Fourth Quarter Revenue up 29% to $50.4 Million

Strong Revenue Growth in both Defibrillation and Cardiac Monitoring

Full Year Revenue Growth of 17% to $182 Million and EPS of $0.37

BOTHELL, Wash., Feb. 28 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, today announced record results for the fourth quarter and full year ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050913/SFTU139LOGO)

Revenue for the quarter was $50.4 million, an increase of 29% over the prior year period. The growth reflected an increase in defibrillation and cardiac monitoring sales of 48% and 16%, respectively. Domestic automated external defibrillator (AED) sales grew 30% from the prior year's fourth quarter, while international AED sales rose 68% for the quarter, driven by strong growth throughout Europe and Asia. The Company reported net income of $2.4 million, or $0.10 per diluted share in the fourth quarter, compared to a small net loss of $35,000, or $0.00 per share in the fourth quarter of 2006.

For the full year 2007, revenue totaled $182.1 million, an increase of 17% compared to revenue of $155.4 million for 2006. The Company reported net income of $8.5 million for the year, or $0.37 per diluted share. Net income for the year included a non-cash benefit and related cash expenses associated with litigation that was settled in 2007. Excluding these litigation-related items, pro forma net income would have been $7.1 million, or $0.31 per diluted share.

2007 Accomplish
'/>"/>

SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Corporate and Political PR Pro to Lead Sudden Cardiac Arrest Association
3. Family History Has Strong Effect on Cardiac Risk
4. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
5. Cardiac Science to Present at the UBS Global Life Sciences Conference
6. Cardiac Science Applauds Mass AED Training of Pittsburgh Educators
7. Guidelines help patients reduce risk of cardiac event before surgery
8. Cardiac Science Named to Deloittes Technology Fast 50 for Washington State
9. Cleveland Clinic and The Larry King Cardiac Foundation Partner to Provide Heart Surgery to Those in Need
10. Cardiac Science Releases New Cardiac Rehabilitation System
11. Cardiac Artery Trouble Boosts Family Heart Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...n of the skin that affects more than 80 percent of...tress has often been cited // as a source of acne,... Twenty-two university students participated in th...one academic examination within the time of the st...
...ertaken at Wake Forest University Baptist Medical ... signs after research in monkeys suggested //that ... fact affect heart attack severity. At an annual...se Society in Washington, D.C. today, Dr. J. Koudy...
... report more than half a million women in developi... the Partnership for Safe Motherhood and Newborn H...nd the world to ensure that a woman does not die w...eport indicates that the needs are wide-ranging - ...
...run by nurses and dieticians have been found effec...ther analysis // has shown they work only when the...esterol-lowering drugs. Researchers looked at a pr...medications from their physicians and were only “c...
Other Medicine News:Health News:Hormone therapy may affect heart attack severity in women 2Health News:WHO acts to reduce the maternal death toll 2
(Date:9/4/2008)... Updated Survival Data for Ipilimumab...swire-FirstCall/ -- Medarex, Inc.,(Nasdaq: MEDX )...ipilimumab,an investigational anti-CTLA-4 antibod...presentations at the 33rd Congress of the European...ptember 12-16, 2008 in Stockholm.,Many of the foll...
(Date:9/4/2008)... Data Announcements Remain on Schedule with Tw...ge Clinical Data Release in November 2008, BRIDGE...maceuticals,Inc., a specialty pharmaceutical comp... metabolic disease, today announced the appointmen...rd of directors., Peter Garrambone,s career inclu...
(Date:9/3/2008)... NANJING, China, Sept. 3 /PRNewswire-FirstCal...a leading manufacturer and supplier of,branded gen...ted,anti-cancer biotech product Endu (also known a...s of Endu Phase IV clinical study., At the reques...al study,to further validate the safety and therap...
(Date:9/3/2008)... September is National Vascular Diseas.../- Diffusion Pharmaceuticals,LLC, a c...zing new drugs,for the treatment of unmet medical ... patients in a Phase I/II clinical trial of its le...The trial, designated NCT00725881,on the clinicalt...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees 136 1UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees 136 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 1Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 2Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business 134 3Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing 125 1Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing 125 2Soccer burns more fat than jogging 123 1Soccer burns more fat than jogging 123 2Soccer burns more fat than jogging 123 3
...- Cytogen,Corporation (NASDAQ: CYTO) reported upda...uating QUADRAMET(R) (samarium Sm-153,lexidronam in...),Millennium Pharmaceuticals, Inc.) in patients w...ts were presented today in a,poster titled, "Phase... Multiple Myeloma," by James Berenson, M.D., Medic...
...tion against,infection with virus types beyond 16 ...ine, PHILADELPHIA, June 27, 2007 /PRNewswire-First...se III study show that,CERVARIX(R), the GlaxoSmith...up to 100 percent protection against advanced prec...f human papillomavirus,types 16 and 18. The study...
Other Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7
...ment introduction. The design of the introducer fe...ition profile between the introducer sheath and in...h fascial tissue and strictured areas. Proximal re...ducer sheath and introducer dilator during sheath ...
Used for catheter or instrument introduction. The dual knobs allow the sheath to be peeled away and removed. The maximum diameter of the catheter or instrument to be introduced should be measured to
Used to establish a percutaneous tract into the renal pelvis for catheter placement or stone manipulation. Supplied sterile in peel-open packages. Intended for one-time use.
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: